• Most of lipid lowering agents have many therapeutic problems

  2023-12-01

  

  Most of lipid-lowering agents have many therapeutic problems with severe side effects, while dietary fibers as lipid lowering therapy are safer. Chitosan (CS) is a dietary fiber biodegradable, biocompatible and has many health benefits including wound healing, antiinflammatory, anti-cancers, immune-

• br Concluding remarks br Definition

  2023-12-01

  

  Concluding remarks Definition Prion diseases are fatal neurodegenerative disorders that are caused by an unconventional agent that is neither bacterial nor viral, but is in essence an infectious misfolded amyloidogenic protein, termed a prion (Prusiner, 1982). Once considered highly controvers

• br Acknowledgements This work was supported by

  2023-12-01

  

  Acknowledgements This work was supported by Programme Grants from the MRC and the Wellcome Trust (SGC-C and MF). CB was in receipt of a Marie Curie Intra-European Fellowship during part of this work. We thank past and present members of our group for numerous valuable discussions throughout these

• br New AMPK activators Fenofibrate is a

  2023-11-30

  

  New AMPK activators Fenofibrate is a drug of the fibrate class used for the treatment of dyslipidemia [53] but is also an agent that could alleviate DN-induced alterations through AMPK activation (Fig. 2). Streptozotocin-induced diabetic rats treated with fenofibrate improved in not only renal fu

• The results show that a

  2023-11-30

  

  The results show that a tonic action of ACh on respiration is lacking. However, it is clear that muscarinic cholinergic mechanisms can modulate both eupneic breathing and the cough reflex. When these mechanisms are brought into action is obscure and only tentative proposals can be advanced. ACh in t

• amd3100 synthesis Taniyama et al reported a female with

  2023-11-30

  

  Taniyama et al. reported a female with infertility who had a homozygous T-to-A transversion at nucleotide position g.2472 in exon 3 of the CYP17A1 gene (mutation Y201N) and decreased 17-hydroxylase and 17,20-lyase activities of 17OHD, diagnosed by hormonal profile but not molecular genetics, who pr

• In this scenario the receptor tyrosine

  2023-11-30

  

  In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5mo, respectively, hazard ratio (HR) = 0.42; 95% CI: 0.32–0.54; Palcohol dehy

• br Structure of V ATPase V

  2023-11-30

  

  Structure of V-ATPase V-ATPase is a highly conserved multi-subunit enzyme that uses energy from ATP hydrolysis to transport protons across membranes [2], [3], [4]. It consists of two major functional domains, V1 and V0 (Fig. 1). The former has eight different subunits (A, B, C, D, E, F, G, and H)

• Acl converts cytosolic citrate CoA and ATP into acetyl CoA

  2023-11-30

  

  Acl converts cytosolic citrate, CoA and ATP into acetyl-CoA, ADP+Pi and oxaloacetate (Fig. 1). This cytosolic enzyme is present in few Prokaryotes and in all Eukaryotes, but not in non-oleaginous yeasts [14]. Thus, this enzyme was presumed to be essential for FA synthesis [1], [13], [15]. In most mi

• vx 765 br Acknowledgments This study is a part of

  2023-11-30

  

  Acknowledgments This study is a part of a MSc thesis and supported by Scientific Research Projects Coordination Unit of Akdeniz University (grant number: 2011.02.0122.007). Introduction Apelin receptor (putative receptor protein related to the angiotensin receptor AT1, APJ) belongs to the G-p

• According to the present observations the Ampk

  2023-11-30

  

  According to the present observations, the Ampkα1 isoform promotes AP-1 transcriptional activity and thereby fosters droperidol of AP-1 target genes in cardiomyocytes via activation of Pkcζ. The transcription factor AP-1 plays a decisive role during cardiac remodeling [24], [25], [26], [37]. AP-1 mo

• In the present study a

  2023-11-29

  

  In the present study, a splice acceptor site mutation (c.1769-1G > C) was identified in AR gene from patients with CAIS. The c.1769-1G > C mutation results in replacement of the normal sequence (CAG/G) with a new sequence (CAC/G) at the splice acceptor site of intron 2. In the splice acceptor site r

• The primary structure of the A peptide can be divided

  2023-11-29

  

  The primary structure of the Aβ peptide can be divided into four regions based on hydrophobicity. The N-terminal residues 1–16 comprise the first hydrophilic region, which also contains the metal binding site. More specifically, side chain carboxylate of D1 and the side chain nitrogens of H6, H13 an

• br Introduction Nonalcoholic fatty liver disease NAFLD is

  2023-11-29

  

  Introduction Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic spectrum of liver pathologies associated with excessive accumulation of fat in the liver. This spectrum is continuous but can be graded based on pathological features; in increasing severity, these are: bland steatosis,

• Imatinib was first approved for the treatment of

  2023-11-29

  

  Imatinib was first approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in 2001 [25]. This first approved small molecule antagonist is quite unusual in that it provides a durable response that lasts for more than a decade in the majority of patients. Imatinib h

14166 records 71/945 page Previous Next First page 上5页 7172737475 下5页 Last page